TY - JOUR
T1 - Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe – an update of the European Union Drugs Agency technical protocol, 2024
AU - Sperle, Ida
AU - Seyler, Thomas
AU - Pericoli, Filippo
AU - Duffell, Erika
AU - Hutchinson, Sharon
AU - Jauffret-Roustide, Marie
AU - Kåberg, Martin
AU - Ķīvīte-Urtāne, Anda
AU - Seguin-Devaux, Carole
AU - Sypsa, Vana
AU - Zimmermann, Ruth
N1 - Funding:
This work was funded by European Union Drugs Agency (EUDA) through contract CT.22.HEA.0108.1.0
Publisher Copyright:
© 2025, European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2025/7/31
Y1 - 2025/7/31
N2 - Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which cov-ers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemio-logical situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in vari-ous settings. To reach the World Health Organization’s goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the dispropor-tionately affected PWID population is needed.
AB - Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which cov-ers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemio-logical situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in vari-ous settings. To reach the World Health Organization’s goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the dispropor-tionately affected PWID population is needed.
KW - Humans
KW - Substance Abuse, Intravenous/epidemiology
KW - Europe/epidemiology
KW - European Union
KW - HIV Infections/epidemiology
KW - Hepatitis C/epidemiology
KW - Hepatitis B/epidemiology
KW - Prevalence
KW - Population Surveillance/methods
KW - Harm Reduction
KW - Cross-Sectional Studies
UR - https://www.scopus.com/pages/publications/105012790014
UR - https://pubmed.ncbi.nlm.nih.gov/40747572/
U2 - 10.2807/1560-7917.ES.2025.30.30.2500007
DO - 10.2807/1560-7917.ES.2025.30.30.2500007
M3 - Article
C2 - 40747572
SN - 1560-7917
VL - 30
JO - Eurosurveillance
JF - Eurosurveillance
IS - 30
M1 - pii=2500007
ER -